Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine.
about
GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitusAntioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.Meta-analysis of oxidative stress in schizophrenia.Polyphenols from Berries of Aronia melanocarpa Reduce the Plasma Lipid Peroxidation Induced by Ziprasidone.A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics.Oxidative stress and psychological disorders.Blood-brain barrier dysfunction in brain diseases: clinical experience.Reliability of malondialdehyde as a biomarker of oxidative stress in psychological disorders.Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro.Antipsychotic-like effect of minocycline in a rat model.Winter/summer seasonal changes in malondialdehyde formation as a source of variance in oxidative stress schizophrenia research.The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro.Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation.Urinary biopyrrins: potential biomarker for monitoring of the response to treatment with anxiolytics.Epicatechin inhibits human plasma lipid peroxidation caused by haloperidol in vitro.Mn-superoxide dismutase activity is associated with orofacial involuntary movements in schizophrenia patients with tardive dyskinesia.Effect of atypical antipsychotics on antioxidant enzyme activities in human erythrocytes (in vitro study).The complex association between the antioxidant defense system and clinical status in early psychosis.Antipsychotic-like effect of trimetazidine in a rodent model.Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial
P2860
Q30430711-7B5B601F-ECD5-4781-A5B6-0AE851F55C92Q33350202-34B92D2E-A1A0-47A2-B5D4-2929C8043879Q33601360-82D63C05-3A8D-43CA-B6B5-C9CD1F0BDDF4Q33904833-58D8A4D3-F410-472F-B461-335EA7D87DB8Q34507173-8A8B3A21-A1A3-4EC3-94AE-06044635978EQ37661360-BB96A59A-126C-4650-87C5-9841EB22255EQ38058370-80493528-8258-4A1A-A861-529F1A122CFAQ41143093-916B8596-8695-4CCB-A29D-C2033A6DB281Q42745478-267A202F-85BB-4414-9700-73F5CE648A3EQ43015622-FEE08AA3-2210-4AE2-8A03-063B787A0E80Q43692301-C77172E3-216F-47D2-B77D-F0DADCB2281EQ45896435-D0D26EE7-4CF9-49C6-ADF5-E9D16B6C5DADQ46117836-34F7519F-B414-44D5-A353-7B0D4DD8438FQ46164184-7261B35F-12F4-4811-A337-FB755D852B28Q48690651-B8EC7605-2C74-4C65-8F7E-CED6752B9F5BQ50507983-1BA439CC-76DF-40A5-8ED5-75D10AE6F12DQ50602362-95EB0425-500E-4F57-AB2C-4127FAA2E4A2Q50736892-238B947E-B1EB-4C8B-993E-2F04749FD40BQ52308849-58F2F067-9C41-48DC-A5AE-7ABEE2377781Q54574268-DBDFD349-86B6-43B9-BECB-66C6A56F9E25Q58842329-69CDB838-3575-4FBA-B385-544A5493C751
P2860
Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Elevated serum superoxide dism ...... with haloperidol or clozapine.
@en
Elevated serum superoxide dism ...... with haloperidol or clozapine.
@nl
type
label
Elevated serum superoxide dism ...... with haloperidol or clozapine.
@en
Elevated serum superoxide dism ...... with haloperidol or clozapine.
@nl
prefLabel
Elevated serum superoxide dism ...... with haloperidol or clozapine.
@en
Elevated serum superoxide dism ...... with haloperidol or clozapine.
@nl
P50
P1476
Elevated serum superoxide dism ...... with haloperidol or clozapine.
@en
P2093
Mirian Salvador
Paulo Silva Belmonte-de-Abreu
P304
P356
10.1016/J.PNPBP.2005.11.009
P577
2006-01-19T00:00:00Z